Outbreak of COVID-19 was one of the deadliest health hazards encountered in the history of modern civilisation that claimed at least three million lives within a span of two years. The mortality and morbid conditions caused by COVID-19 were found to be associated with several underlying pathological mechanisms like hyper-inflammatory-immune response and coagulopathy. After infection, interaction of COVID-19 spike proteins with angiotensin-converting enzyme-2 receptors on cells initiates a cascade of events of biomolecular interaction in the affected person which culminates into fatal conditions like acute respiratory distress syndrome and multiple organ dysfunction syndrome. COVID-19-associated coagulopathy has been identified as one of the main culprits behind the symptoms and poor prognosis of the COVID-19, and its control through concerned medications became one of the determinants of the treatment outcome of the COVID-19. COVID-19-associated coagulopathy is a condition characterised by activation of microvascular blood clotting mediated by thrombin–fibrin interaction and involvement of activated platelets. This chapter discusses the molecular mechanism involved in the onset and progression of coagulopathy, biomarkers used to identify the severity level of coagulopathy and resulting complications. Treatment strategy specifically using anti-platelet drugs and anti-coagulants to control the coagulopathy has also been discussed in this chapter. Results of several observational studies, clinical trials and meta-analyses were thoroughly examined and have been included in this chapter. It is expected that this chapter will help clinicians and researchers to design and develop new treatment strategies for coagulopathy and related disease in general, and for COVID-19-associated coagulopathy in particular.